SAG protects human neuroblastoma SH-SY5Y cells against 1-methyl-4-phenylpyridinium ion (MPP+)-induced cytotoxicity via the downregulation of ROS generation and JNK signaling

Neuroscience Letters

Volumn 413, Issue 2, 2007, Pages 132-136

  Kim, Sun Yee ^a   Kim, Mi Yeon ^a   Mo, Jung Soon ^a   Park, Jeen Woo ^b   Park, Hee Sae ^a  

^a Chonnam National University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

Cell viability; JNK1; MPP+; Parkinson's disease; SAG; SH SY5Y human neuroblastoma

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; GENE PRODUCT; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PROTEIN SAG; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CELL PROTECTION; CELL STRAIN SH SY5Y; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; GENE; GENE OVEREXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SAG GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSIENT TRANSFECTION;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE KINASE 1; MICE; NEUROBLASTOMA; NEURONS; NEUROTOXINS; NIH 3T3 CELLS; OXIDATIVE STRESS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; RNA-BINDING PROTEINS;

EID: 33846611418     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.11.074     Document Type: Article

References (31)

1. Bossy-Wetzel E., Schwarzenbacher R., and Lipton S.A. Molecular pathways to neurodegeneration. Nat. Med. 10 Suppl. (2004) S2-S9
2. Cassarino D.S., Halvorsen E.M., Swerdlow R.H., Abramova N.N., Parker Jr. W.D., Sturgill T.W., and Bennett Jr. J.P. Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappaB in cellular models of Parkinson's disease. J. Neurochem. 74 (2000) 1384-1392
3. Chanalaris A., Sun Y., Latchman D.S., and Stephanou A. SAG attenuates apoptotic cell death caused by simulated ischaemia/reoxygenation in rat cardiomyocytes. J. Mol. Cell Cardiol. 35 (2003) 257-264
4. + in the rat. Neurochem. Int. 40 (2002) 169-179
5. Chun H.S., Gibson G.E., DeGiorgio L.A., Zhang H., Kidd V.J., and Son J.H. Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J. Neurochem. 76 (2001) 1010-1021
6. Duan H., Wang Y., Aviram M., Swaroop M., Loo J.A., Bian J., Tian Y., Mueller T., Bisgaier C.L., and Sun Y. SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. Mol. Cell Biol. 19 (1999) 3145-3155
7. Eriksen J.L., Wszolek Z., and Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch. Neurol. 62 (2005) 353-357
8. +, and analogs. Evidence against a "redox cycling" mechanism in MPTP neurotoxicity. Biochem. Biophys. Res. Commun. 147 (1987) 1095-1104
9. +) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170 (1990) 1049-1055
10. He H., Tan M., Pamarthy D., Wang G., Ahmed K., and Sun Y. CK2 phosphorylation of SAG at Thr10 regulates SAG stability, but not its E3 ligase activity. Mol. Cell Biochem. (2006)
11. Huang Y., Duan H., and Sun Y. Elevated expression of SAG/ROC2/Rbx2/Hrt2 in human colon carcinomas: SAG does not induce neoplastic transformation, but antisense SAG transfection inhibits tumor cell growth. Mol. Carcinog. 30 (2001) 62-70
12. Kim S.Y., Bae Y.S., and Park J.W. Thiol-linked peroxidase activity of human sensitive to apoptosis gene (SAG) protein. Free Radic. Res. 36 (2002) 73-78
13. Kim Y.S., Lee J.Y., Son M.Y., Park W., and Bae Y.S. Phosphorylation of threonine 10 on CKBBP1/SAG/ROC2/Rbx2 by protein kinase CKII promotes the degradation of IkappaBalpha and p27Kip1. J. Biol. Chem. 278 (2003) 28462-28469
14. +): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci. Lett. 48 (1984) 87-92
15. Marsden C.D. Parkinson's disease. Lancet 335 (1990) 948-952
16. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005) 57-87
17. Morris H.R. Genetics of Parkinson's disease. Ann. Med. 37 (2005) 86-96
18. Park H.S., Lee J.S., Huh S.H., Seo J.S., and Choi E.J. Hsp72 functions as a natural inhibitory protein of c-Jun N-terminal kinase. Embo. J. 20 (2001) 446-456
19. Robertson H.A. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci. 15 (1992) 201-206
20. Saporito M.S., Thomas B.A., and Scott R.W. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 75 (2000) 1200-1208
21. Sasaki H., Yukiue H., Kobayashi Y., Moriyama S., Nakashima Y., Kaji M., Fukai I., Kiriyama M., Yamakawa Y., and Fujii Y. Expression of the sensitive to apoptosis gene, SAG, as a prognostic marker in nonsmall cell lung cancer. Int. J. Cancer 95 (2001) 375-377
22. Son M.Y., Park J.W., Kim Y.S., Kang S.W., Marshak D.R., Park W., and Bae Y.S. Protein kinase CKII interacts with and phosphorylates the SAG protein containing ring-H2 finger motif. Biochem. Biophys. Res. Commun. 263 (1999) 743-748
23. Sun Y. Alterations of SAG mRNA in human cancer cell lines: requirement for the RING finger domain for apoptosis protection. Carcinogenesis 20 (1999) 1899-1903
24. Sun Y., Tan M., Duan H., and Swaroop M. SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions. Antioxid. Redox Signal. 3 (2001) 635-650
25. Swaroop M., Bian J., Aviram M., Duan H., Bisgaier C.L., Loo J.A., and Sun Y. Expression, purification, and biochemical characterization of SAG, a ring finger redox-sensitive protein. Free Radic. Biol. Med. 27 (1999) 193-202
26. Tatton W.G., Chalmers-Redman R., Brown D., and Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol. 53 Suppl. 3 (2003) S61-S70 (discussion S70-2)
27. Umemura T., Naoi M., Takahashi T., Fukui Y., Yasue T., Ohashi M., and Nagatsu T. Cytotoxic effect of 1-methyl-4-phenylpyridinium ion on human melanoma cell lines, HMV-II and SK-MEL-44, is dependent on the melanin contents and caused by inhibition of mitochondrial electron transport. Biochem. Med. Metab. Biol. 44 (1990) 51-58
28. Vila M., and Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. 10 Suppl. (2004) S58-S62
29. Wang W., Ma C., Mao Z., and Li M. JNK inhibition as a potential strategy in treating Parkinson's disease. Drug News Perspect. 17 (2004) 646-654
30. Xia X.G., Harding T., Weller M., Bieneman A., Uney J.B., and Schulz J.B. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10433-10438
31. Yang G.Y., Pang L., Ge H.L., Tan M., Ye W., Liu X.H., Huang F.P., Wu D.C., Che X.M., Song Y., Wen R., and Sun Y. Attenuation of ischemia-induced mouse brain injury by SAG, a redox-inducible antioxidant protein. J. Cereb. Blood Flow Metab. 21 (2001) 722-733